Bulletin from Annual General Meeting of BioGaia AB (publ)

The Annual General Meeting of BioGaia AB (publ) was held on 7 May 2026 at 4.00 pm at Klara Konferens & Happynings, Klarabergsviadukten 90, Stockholm, at which the shareholders passed the resolutions set out below.

• Adoption of the income statement and balance sheet and the consolidated income statement and consolidated balance sheet.
• Discharge from liability for the Board members and the CEO.
• A dividend of SEK 1.64 per share plus an extra dividend of SEK 2.36 per share, resulting in a total dividend of SEK 4.00 per share, with a record date of 11 May 2026, and a grant of SEK 5.6 million for charitable purposes, of which SEK 4.4 million to “The Foundation to Prevent Antibiotic Resistance” and SEK 1.2 million to other foundations/organisations that operate in the areas of charitable or comparable purposes, as determined by the Board of Directors. Dividends are expected to be disbursed by Euroclear Sweden AB on 15 May 2026.
• The number of Board members shall be six without deputies and re-election of Mauricio Graber, David Dangoor, Barbro Fridén, Anthon Jahreskog and Vanessa Rothschild and, and new election of Amy Byrick, as Board members.
• Re-election of Mauricio Graber as Board Chairman and David Dangoor as Vice Board Chairman.
• The auditor shall be a registered accounting firm and re-election of the registered accounting firm Deloitte AB.
• Board member remuneration in an amount of SEK 1,500,000 to the Board Chairman, SEK 1,000,000 to the Vice Board Chairman, SEK 500,000 to each of the other Board members elected by the General Meeting, SEK 150,000 to the chairman of the audit committee, and SEK 100,000 each to the other members of the audit committee, and SEK 100,000 to the chairman of the remuneration committee, and SEK 50,000 to each of the other members of the remuneration committee. In addition, a fee of SEK 20,000 per physical Board meeting shall be paid to Board members who are not resident in Sweden. Board members may also be entitled to reasonable travel expenses for their participation in the work of the Board and its committees.
• Auditors’ fee shall be paid according to approved account.
• Resolution on a nomination committee in accordance with the nomination committee’s proposal.
• Approval of the Board of Directors' remuneration report.
• Resolution to implement Performance Share Program 2026/2029, regarding a directed issue of warrants to the company to ensure delivery of shares and to cover any cash flow effects resulting from social security contributions in connection with the program, and regarding approval of the transfer of warrants or shares to participants in the program. The detailed terms and conditions of the program are set out in the notice to the Annual General Meeting.

For more detailed information on the content of the resolutions, please refer to the full notice of the Annual General Meeting, which is available on the Company's website, www.biogaiagroup.com. The minutes of the Annual General Meeting will be made available on the aforementioned website within two weeks of the date of the meeting.
 

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Alexander Kotsinas, CFO
Email: [email protected]
Phone: +46(0)735 00 11 11

Theresa Agnew, President and CEO
Email: [email protected]
Phone: +46(0)8 555 293 00
 

About BioGaia
BioGaia is a Swedish probiotics company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, manufactures, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com